Minitab Acquires Effex to Advance Modern Design of Experiments Using a Proprietary Design Catalog and Artificial Intelligence

Minitab, LLC, a global leader in data collection, predictive analytics, and process improvement solutions for manufacturers and organizations worldwide, today announced the acquisition of the Effex ...

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and ...